Cardiovascular Effects of CART Cell Therapy (CVE-CART)
Status
Conditions
Details and patient eligibility
About
This is an observational study aiming to prospectively define the rate of occurrence, natural history and progression of cardiac dysfunction in adults, and to identify the patients at high risk of developing cardiovascular events. The study enrolls patients prior to infusion with CART cell therapy and follows them with serial echocardiography, cardiac biomarkers, clinical data, and quality of life questionnaire.
Full description
Patients have echo, blood draw, and QoL survey prior to CART infusion, then 2 days, 1 week, 1 month and 6 months following CART infusion. If patients experiences CRS, study team acquires echo within 72 hours of onset. As part of an optional substudy, patients wear an event monitor for 10 days, starting day of CART infusion.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- At least 18 years of age
- Diagnosed with CD19+ malignancy undergoing treatment with CART cells
Exclusion criteria
- Unable to provide informed consent
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal